Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10713544 | 0.82 | MAPT (0.43) | KMT2AMEN1PTGS2MAPTGFER | |
| SCHEMBL29367971 | 0.80 | AHR (0.46) | KMT2AMEN1PTGS2MAPTSMN1; SMN2 | |
| SCHEMBL9666112 | 0.79 | POLB (0.47) | KMT2AMEN1POLBPTGS2MAPT | |
| SCHEMBL9863112 | 0.77 | S1PR1 (0.33) | KMT2AMEN1POLB | |
| SCHEMBL9666810 | 0.76 | ESR2 (0.44) | PTGS2 | |
| SCHEMBL21611100 | 0.76 | KCNH2 (0.38) | SMN1; SMN2 | |
| SCHEMBL5140737 | 0.76 | PDK2 (0.41) | MAPTSMN1; SMN2 | |
| SCHEMBL9862968 | 0.76 | KCNH2 (0.40) | KMT2AMEN1MAPTSMN1; SMN2KMO | |
| SCHEMBL11082623 | 0.76 | ALDH1A1 (0.48) | KMT2AMEN1MAPK10MAPTSMN1; SMN2 | |
| SCHEMBL9863109 | 0.75 | KCNH2 (0.35) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | KMT2A 1976/4885MEN1 3767/4885POLB 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.